A CD44−/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Treatment of metastatic breast cancer: second line and beyond

(2010) H. Roche et al.   ANNALS OF ONCOLOGY

Cancer stem cells: problems for therapy?

(2010) Malcolm R Alison et al.   JOURNAL OF PATHOLOGY

Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis

(2010) Glen Kristiansen et al.   LABORATORY INVESTIGATION

The clinicopathological significance of CD44+/CD24−/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast

(2010) Weidong Li et al.   PATHOLOGY RESEARCH AND PRACTICE

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

(2009) E. A. Rakha et al.   CLINICAL CANCER RESEARCH

CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation

(2009) Mohamed A.H. Ahmed et al.   INFLAMMATORY BOWEL DISEASES

CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer

(2009) M A H Ahmed et al.   JOURNAL OF CLINICAL PATHOLOGY

The clinicopathologic and prognostic significance of CD44+/CD24−/low and CD44−/CD24+ tumor cells in invasive breast carcinomas

(2008) Eleni Mylona et al.   HUMAN PATHOLOGY

Cancer stem cells: implications for the progression and treatment of metastatic disease

(2008) A.K Croker et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute